Nektar Therapeutics | NKTR - Ebit



金融业
股票价格
USD
资产
USD 280.41M
现金及等价物
USD 15.12M
销售成本
USD 4.44M
流动资产
USD 266.27M
流动负债
USD 53.54M
债务
USD 0
股息收益率
0
EBIT
USD -19.09M
EBITDA
USD -31.81M
员工
137
EPS每股收益
USD -1.35
股本和储备
USD 89.83M
销售毛利
USD 21.81M
债务利息支出
USD 9.77M
利息收入
USD -0.18
贷款资金
USD 63.16M
市值
USD 13.75B
净收入
USD -36.08M
营业费用
USD 40.9M
营业利润
USD -19.09M
普通股股本
USD 20.38M
税前利润
USD -34.7M
销售收入
USD 21.81M
销售和管理费用
USD 10.17M
股票
USD 14.46M
贸易债权人
USD 10.77M
应收帐款人
USD 1.78M


Ebit 更改 日
Agios Pharmaceuticals USD -110.02M 11.55M 2026-03
ALKERMES USD -48.28M 37.33M 2026-03
Alterity Therapeutics Limited AUD -8.07M 302.4K 2025-12
Amgen USD 3.83B 130M 2026-03
Baxter International USD 66M 280.2M 2026-03
BioCryst Pharmaceuticals USD 260.38M 230.79M 2025-12
Biogen USD 514.3M 502.8M 2026-03
Bristol-Myers Squibb USD 3.56B 90M 2026-03
Cara Therapeutics USD -5.94M 3.55M 2025-09
Cipla INR 6.14B 3.63B 2026-03
Dr.Reddys Laboratories INR 888M 13.05B 2026-03
Eisai JPY -10.31B 30.35B 2026-03
Eli Lilly USD 9.78B 792M 2026-03
Esperion Therapeutics USD 85.23M 95.19M 2025-12
Exelixis USD 251.34M 15.43M 2026-03
Gilead Sciences USD 2.68B 284M 2026-03
GlaxoSmithKline GBP 2.29B 856M 2026-03
Grifols EUR 320.55M 91.01M 2025-12
Halozyme Therapeutics USD -61.77M 26.64M 2026-03
Incyte USD 344.17M 39.71M 2026-03
Ionis Pharmaceuticals USD -118M 97M 2026-03
Ironwood Pharmaceuticals USD 33.22M 7.58M 2024-12
Karyopharm Therapeutics USD -17.84M 8.44M 2025-12
MacroGenics USD -31.88M 19.79M 2026-03
Merck USD -1.88B 8.12B 2026-03
Nektar Therapeutics USD -19.09M 15.26M 2025-12
Neurocrine Biosciences USD 214.6M 13.3M 2026-03
Novartis USD 4.18B 118M 2026-03
Pfizer USD 4.99B 340M 2026-03
Roche Holding CHF 9.56B 2.1B 2025-12
Sarepta Therapeutics USD 358.43M 768.52M 2026-03
Takeda JPY -13.62B 271.11B 2026-03
Teva Pharmaceutical Industries USD 758M 181M 2026-03
Xencor USD -77.86M 24.23M 2026-03